Stock code: 688202 Stock abbreviation: Medicilon Announcement No.: 2024-056

Shanghai Medicililon Biopharmaceutical Co., Ltd

Announcement of the resolution of the 22nd meeting of the third board of supervisors

The Board of Supervisors and all supervisors of the Company guarantee that there are no false records, misleading statements or major omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

1. The convening of the meeting of the board of supervisors

Shanghai Medicilon Biopharmaceutical Co., Ltd. (hereinafter referred to as "the Company") is the second of the third board of supervisors

The twelve meetings were held by correspondence on 13 December 2024. The notice of this meeting was issued in 2024

On December 9, the year was sent to all supervisors by e-mail. The meeting was convened and presided over by Mr. Zeng Xiancheng, Chairman of the Board of Supervisors, and there were 3 supervisors who should attend the meeting and 3 supervisors who actually attended the meeting. The convening and convening of this meeting is in accordance with the relevant provisions of the Company Law of the People's Republic of China (hereinafter referred to as the "Company Law") and other laws, administrative regulations and the Articles of Association, and the meeting is legal and valid.

2. Deliberations of the Board of Supervisors

The meeting was deliberated by the supervisors attending the meeting and passed the following proposals by written vote:

(1) Reviewed and approved the "Proposal on Abolishing Part of the 2020 Restricted Shares Granted and Not Vested"

The restrictive shares that have been granted and have not yet vested are in accordance with the Company Law, the Securities Law of the People's Republic of China, the Administrative Measures for Equity Incentives of Listed Companies, the Rules for the Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange, the Self-Regulatory Guide for Listed Companies on the Science and Technology Innovation Board No. 4 - Disclosure of Equity Incentive Information and other laws and regulations, as well as the relevant provisions of the Company's 2020 restricted stock incentive plan, and there is no harm to the interests of shareholders. Therefore, we agree to the forfeiture of the restricted stock that has not yet vested in the Company.

For details, please refer to the "2020 Term of the Invalid Part Granted to the Invalid Part of Shanghai Medicilon Biopharmaceutical Co., Ltd." published on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same day

Announcement of Institutional Stocks.

The result of the vote: 3 votes in favor, 0 votes against, and 0 abstentions.

The announcement is hereby made.

Board of Supervisors of Shanghai Medicilon Biopharmaceutical Co., Ltd

December 14, 2024